Induction of CXCL10 chemokine in adrenocortical cells by stimulation through toll-like receptor 3

Molecular and Cellular Endocrinology

Volumn 365, Issue 1, 2013, Pages 75-83

  Bratland, Eirik ^a   Hellesen, Alexander ^a   Husebye, Eystein S ^a,b  

^a UNIVERSITY OF BERGEN   (Norway)

^b HAUKELAND UNIVERSITY HOSPITAL   (Norway)

Author keywords

Addison's disease; CXC chemokine ligand 10; Interferon ; Interferon inducible protein 10; Toll like receptor 3

Indexed keywords

ALPHA INTERFERON; BETA INTERFERON; CHEMOKINE RECEPTOR CXCR3; CXCL9 CHEMOKINE; GAMMA INTERFERON; GAMMA INTERFERON INDUCIBLE PROTEIN 10; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; POLYINOSINIC POLYCYTIDYLIC ACID; STAT1 PROTEIN; TOLL LIKE RECEPTOR 3; TUMOR NECROSIS FACTOR ALPHA; VIRUS RNA;

ADDISON DISEASE; ADRENAL CORTEX CELL; ANIMAL CELL; ARTICLE; AUTOIMMUNITY; CONTROLLED STUDY; CYTOKINE PRODUCTION; CYTOKINE RELEASE; ENVIRONMENTAL FACTOR; HUMAN; HUMAN CELL; NONHUMAN; PATHOGENESIS; PRIORITY JOURNAL; PROTEIN EXPRESSION; RECEPTOR BINDING; RECEPTOR UPREGULATION;

ADDISON DISEASE; ADRENAL CORTEX; ANIMALS; AUTOANTIGENS; CATTLE; CELL LINE; CELLS, CULTURED; CHEMOKINE CXCL10; HUMANS; INTERFERON INDUCERS; INTERFERON-GAMMA; LEUKOCYTES, MONONUCLEAR; NF-KAPPA B; POLY I-C; RECEPTORS, CXCR3; RECOMBINANT PROTEINS; STAT1 TRANSCRIPTION FACTOR; STEROID 21-HYDROXYLASE; TOLL-LIKE RECEPTOR 3; TUMOR NECROSIS FACTOR-ALPHA;

EID: 84868444480     PISSN: 03037207     EISSN: 18728057     Source Type: Journal    
DOI: 10.1016/j.mce.2012.09.004     Document Type: Article

References (62)

1. Ahmad U., Ali R., Lebastchi A.H., Qin L., Lo S.F., Yakimov A.O., Khan S.F., Choy J.C., Geirsson A., Pober J.S., Tellides G. IFN-gamma primes intact human coronary arteries and cultured coronary smooth muscle cells to double-stranded RNA- and self-RNA-induced inflammatory responses by upregulating TLR3 and melanoma differentiation-associated gene 5. J. Immunol. 2010, 185(2):1283-1294.
2. Alexopoulou L., Holt A.C., Medzhitov R., Flavell R.A. Recognition of double-stranded RNA and activation of NF-kappaB by toll-like receptor 3. Nature 2001, 413(6857):732-738.
3. Antonelli A., Ferrari S.M., Frascerra S., Corrado A., Pupilli C., Bernini G., Benvenga S., Ferrannini E., Fallahi P. Peroxisome proliferator-activated receptor alpha agonists modulate Th1 and Th2 chemokine secretion in normal thyrocytes and Graves' disease. Exp. Cell Res. 2011, 317(11):1527-1533.
4. Bellastella G., Rotondi M., Pane E., Costantini S., Colella C., Calemma R., Capone F., Falorni A., Castello G., Sinisi A.A., Bizzarro A., Chiovato L., Bellastella A., De Bellis A. Simultaneous evaluation of the circulating levels of both Th1 and Th2 chemokines in patients with autoimmune Addison's disease. J. Endocrinol. Invest. 2011, 34(11):831-834.
5. Blomhoff A., Lie B.A., Myhre A.G., Kemp E.H., Weetman A.P., Akselsen H.E., Huseby E.S., Undlien D.E. Polymorphisms in the cytotoxic T lymphocyte antigen-4 gene region confer susceptibility to Addison's disease. J. Clin. Endocrinol. Metab. 2004, 89(7):3474-3476.
6. Bornstein S.R., Rutkowski H., Vrezas I. Cytokines and steroidogenesis. Mol. Cell. Endocrinol. 2004, 215(1-2):135-141.
7. Bratland E., Bredholt G., Mellgren G., Knappskog P.M., Mozes E., Husebye E.S. The purification and application of biologically active recombinant steroid cytochrome P450 21-hydroxylase: The major autoantigen in autoimmune Addison's disease. J. Autoimmun. 2009, 33(1):58-67.
8. Bratland E., Husebye E.S. Cellular immunity and immunopathology in autoimmune Addison's disease. Mol. Cell. Endocrinol. 2011, 336(1-2):180-190.
9. Bratland E., Skinningsrud B., Undlien D.E., Mozes E., Husebye E.S. T cell responses to steroid cytochrome P450 21-hydroxylase in patients with autoimmune primary adrenal insufficiency. J. Clin. Endocrinol. Metab. 2009, 94(12):5117-5124.
10. Caskey M., Lefebvre F., Filali-Mouhim A., Cameron M.J., Goulet J.P., Haddad E.K., Breton G., Trumpfheller C., Pollak S., Shimeliovich I., Duque-Alarcon A., Pan L., Nelkenbaum A., Salazar A.M., Schlesinger S.J., Steinman R.M., Sekaly R.P. Synthetic double-stranded RNA induces innate immune responses similar to a live viral vaccine in humans. J. Exp. Med. 2011, 208(12):2357-2366.
11. Clarke D.L., Clifford R.L., Jindarat S., Proud D., Pang L., Belvisi M., Knox A.J. TNFalpha and IFNgamma synergistically enhance transcriptional activation of CXCL10 in human airway smooth muscle cells via STAT-1, NF-kappaB, and the transcriptional coactivator CREB-binding protein. J. Biol. Chem. 2010, 285(38):29101-29110.
12. Diegelmann J., Beigel F., Zitzmann K., Kaul A., Goke B., Auernhammer C.J., Bartenschlager R., Diepolder H.M., Brand S. Comparative analysis of the lambda-interferons IL-28A and IL-29 regarding their transcriptome and their antiviral properties against hepatitis C virus. PLoS ONE 2010, 5(12):e15200.
13. Doyle S.E., O'Connell R., Vaidya S.A., Chow E.K., Yee K., Cheng G. Toll-like receptor 3 mediates a more potent antiviral response than Toll-like receptor 4. J. Immunol. 2003, 170(7):3565-3571.
14. Dumoutier L., Tounsi A., Michiels T., Sommereyns C., Kotenko S.V., Renauld J.C. Role of the interleukin (IL)-28 receptor tyrosine residues for antiviral and antiproliferative activity of IL-29/interferon-lambda 1: similarities with type I interferon signaling. J. Biol. Chem. 2004, 279(31):32269-32274.
15. Erichsen M.M., Lovas K., Fougner K.J., Svartberg J., Hauge E.R., Bollerslev J., Berg J.P., Mella B., Husebye E.S. Normal overall mortality rate in Addison's disease, but young patients are at risk of premature death. Eur. J. Endocrinol. 2009, 160(2):233-237.
16. Erichsen M.M., Lovas K., Skinningsrud B., Wolff A.B., Undlien D.E., Svartberg J., Fougner K.J., Berg T.J., Bollerslev J., Mella B., Carlson J.A., Erlich H., Husebye E.S. Clinical, immunological, and genetic features of autoimmune primary adrenal insufficiency: observations from a Norwegian registry. J. Clin. Endocrinol. Metab. 2009, 94(12):4882-4890.
17. Erkel G., Rether J., Anke T., Sterner O. S14-95, a novel inhibitor of the JAK/STAT pathway from a Penicillium species. J. Antibiot. (Tokyo) 2003, 56(4):337-343.
18. Gautier G., Humbert M., Deauvieau F., Scuiller M., Hiscott J., Bates E.E., Trinchieri G., Caux C., Garrone P. A type I interferon autocrine-paracrine loop is involved in toll-like receptor-induced interleukin-12p70 secretion by dendritic cells. J. Exp. Med. 2005, 201(9):1435-1446.
19. Gazdar A.F., Oie H.K., Shackleton C.H., Chen T.R., Triche T.J., Myers C.E., Chrousos G.P., Brennan M.F., Stein C.A., La Rocca R.V. Establishment and characterization of a human adrenocortical carcinoma cell line that expresses multiple pathways of steroid biosynthesis. Cancer Res. 1990, 50(17):5488-5496.
20. Gira A.K., Kowalczyk A.P., Feng Y., Swerlick R.A. Iron chelators and hypoxia mimetics inhibit IFNgamma-mediated Jak-STAT signaling. J. Invest. Dermatol. 2009, 129(3):723-729.
21. Harii N., Lewis C.J., Vasko V., McCall K., Benavides-Peralta U., Sun X., Ringel M.D., Saji M., Giuliani C., Napolitano G., Goetz D.J., Kohn L.D. Thyrocytes express a functional toll-like receptor 3: overexpression can be induced by viral infection and reversed by phenylmethimazole and is associated with Hashimoto's autoimmune thyroiditis. Mol. Endocrinol. 2005, 19(5):1231-1250.
22. Hemmi H., Takeuchi O., Kawai T., Kaisho T., Sato S., Sanjo H., Matsumoto M., Hoshino K., Wagner H., Takeda K., Akira S. A toll-like receptor recognizes bacterial DNA. Nature 2000, 408(6813):740-745.
23. Hill N.J., Hultcrantz M., Sarvetnick N., Flodstrom-Tullberg M. The target tissue in autoimmunity - an influential niche. Eur. J. Immunol. 2007, 37(3):589-597.
24. Homma T., Matsukura S., Hirose T., Ohnishi T., Kimura T., Kurokawa M., Ieki K., Odaka M., Suzuki S., Watanabe S., Sato M., Kawaguchi M., Schleimer R.P., Adachi M. Cooperative activation of CCL5 expression by TLR3 and tumor necrosis factor-alpha or interferon-gamma through nuclear factor-kappaB or STAT-1 in airway epithelial cells. Int. Arch. Allergy Immunol. 2010, 152(Suppl. 1):9-17.
25. Jeong J.Y., Choi J.W., Jeon K.I., Jue D.M. Chloroquine decreases cell-surface expression of tumour necrosis factor receptors in human histiocytic U-937 cells. Immunology 2002, 105(1):83-91.
26. Jiang Z., Mak T.W., Sen G., Li X. Toll-like receptor 3-mediated activation of NF-kappaB and IRF3 diverges at toll-IL-1 receptor domain-containing adapter inducing IFN-beta. Proc. Natl. Acad. Sci. USA 2004, 101(10):3533-3538.
27. Kanczkowski W., Zacharowski K., Wirth M.P., Ehrhart-Bornstein M., Bornstein S.R. Differential expression and action of Toll-like receptors in human adrenocortical cells. Mol. Cell. Endocrinol. 2009, 300(1-2):57-65.
28. Kanda N., Watanabe S. Prolactin enhances interferon-gamma-induced production of CXC ligand 9 (CXCL9), CXCL10, and CXCL11 in human keratinocytes. Endocrinology 2007, 148(5):2317-2325.
29. Kato H., Takeuchi O., Sato S., Yoneyama M., Yamamoto M., Matsui K., Uematsu S., Jung A., Kawai T., Ishii K.J., Yamaguchi O., Otsu K., Tsujimura T., Koh C.S., Reis e Sousa C., Matsuura Y., Fujita T., Akira S. Differential roles of MDA5 and RIG-I helicases in the recognition of RNA viruses. Nature 2006, 441(7089):101-105.
30. Kelestimur F. The endocrinology of adrenal tuberculosis: the effects of tuberculosis on the hypothalamo-pituitary-adrenal axis and adrenocortical function. J. Endocrinol. Invest. 2004, 27(4):380-386.
31. Kisand K., Link M., Wolff A.S., Meager A., Tserel L., Org T., Murumagi A., Uibo R., Willcox N., Trebusak Podkrajsek K., Battelino T., Lobell A., Kampe O., Lima K., Meloni A., Ergun-Longmire B., Maclaren N.K., Perheentupa J., Krohn K.J., Scott H.S., Husebye E.S., Peterson P. Interferon autoantibodies associated with AIRE deficiency decrease the expression of IFN-stimulated genes. Blood 2008, 112(7):2657-2666.
32. Kumar A., Zhang J., Yu F.S. Toll-like receptor 3 agonist poly(I:C)-induced antiviral response in human corneal epithelial cells. Immunology 2006, 117(1):11-21.
33. Leonard J.N., Ghirlando R., Askins J., Bell J.K., Margulies D.H., Davies D.R., Segal D.M. The TLR3 signaling complex forms by cooperative receptor dimerization. Proc. Natl. Acad. Sci. USA 2008, 105(1):258-263.
34. Lombardi A., Cantini G., Mello T., Francalanci M., Gelmini S., Cosmi L., Santarlasci V., Degl'Innocenti S., Luciani P., Deledda C., Annunziato F., Forti G., Galli A., Serio M., Luconi M. Molecular mechanisms underlying the pro-inflammatory synergistic effect of tumor necrosis factor alpha and interferon gamma in human microvascular endothelium. Eur. J. Cell Biol. 2009, 88(12):731-742.
35. Loos T., Dekeyzer L., Struyf S., Schutyser E., Gijsbers K., Gouwy M., Fraeyman A., Put W., Ronsse I., Grillet B., Opdenakker G., Van Damme J., Proost P. TLR ligands and cytokines induce CXCR3 ligands in endothelial cells: enhanced CXCL9 in autoimmune arthritis. Lab. Invest. 2006, 86(9):902-916.
36. Lovas K., Husebye E.S. Replacement therapy for Addison's disease: recent developments. Exp. Opin. Investig. Drugs 2008, 17(4):497-509.
37. Malathi K., Dong B., Gale M., Silverman R.H. Small self-RNA generated by RNase L amplifies antiviral innate immunity. Nature 2007, 448(7155):816-819.
38. Marx C., Bornstein S.R., Wolkersdorfer G.W. Cellular immune-endocrine interaction in adrenocortical tissues. Eur. J. Clin. Invest. 2000, 30(Suppl. 3):1-5.
39. Matsumoto M., Kikkawa S., Kohase M., Miyake K., Seya T. Establishment of a monoclonal antibody against human Toll-like receptor 3 that blocks double-stranded RNA-mediated signaling. Biochem. Biophys. Res. Commun. 2002, 293(5):1364-1369.
40. McLeod D.S., Mortimer R.H., Perry-Keene D.A., Allworth A., Woods M.L., Perry-Keene J., McBride W.J., Coulter C., Robson J.M. Histoplasmosis in Australia: report of 16 cases and literature review. Medicine (Baltimore) 2011, 90(1):61-68.
41. McNicol A.M. Class II MHC antigen expression in adrenal cortex. Lancet 1986, 2(8518):1282.
42. Meylan E., Burns K., Hofmann K., Blancheteau V., Martinon F., Kelliher M., Tschopp J. RIP1 is an essential mediator of Toll-like receptor 3-induced NF-kappa B activation. Nat. Immunol. 2004, 5(5):503-507.
43. Nakaya T., Sato M., Hata N., Asagiri M., Suemori H., Noguchi S., Tanaka N., Taniguchi T. Gene induction pathways mediated by distinct IRFs during viral infection. Biochem. Biophys. Res. Commun. 2001, 283(5):1150-1156.
44. Ohmori Y., Hamilton T.A. The interferon-stimulated response element and a kappa B site mediate synergistic induction of murine IP-10 gene transcription by IFN-gamma and TNF-alpha. J. Immunol. 1995, 154(10):5235-5244.
45. Paolo W.F., Nosanchuk J.D. Adrenal infections. Int. J. Infect. Dis. 2006, 10(5):343-353.
46. Pekarek V., Srinivas S., Eskdale J., Gallagher G. Interferon lambda-1 (IFN-lambda1/IL-29) induces ELR(-) CXC chemokine mRNA in human peripheral blood mononuclear cells, in an IFN-gamma-independent manner. Genes Immun. 2007, 8(2):177-180.
47. Pestka S., Langer J.A., Zoon K.C., Samuel C.E. Interferons and their actions. Annu. Rev. Biochem. 1987, 56:727-777.
48. Pisegna S., Pirozzi G., Piccoli M., Frati L., Santoni A., Palmieri G. P38 MAPK activation controls the TLR3-mediated up-regulation of cytotoxicity and cytokine production in human NK cells. Blood 2004, 104(13):4157-4164.
49. Reily M.M., Pantoja C., Hu X., Chinenov Y., Rogatsky I. The GRIP1:IRF3 interaction as a target for glucocorticoid receptor-mediated immunosuppression. EMBO J. 2006, 25(1):108-117.
50. Roep B.O., Kleijwegt F.S., van Halteren A.G., Bonato V., Boggi U., Vendrame F., Marchetti P., Dotta F. Islet inflammation and CXCL10 in recent-onset type 1 diabetes. Clin. Exp. Immunol. 2010, 159(3):338-343.
51. Rotondi M., Chiovato L., Romagnani S., Serio M., Romagnani P. Role of chemokines in endocrine autoimmune diseases. Endocrinol. Rev. 2007, 28(5):492-520.
52. Rotondi M., Falorni A., De Bellis A., Laureti S., Ferruzzi P., Romagnani P., Buonamano A., Lazzeri E., Crescioli C., Mannelli M., Santeusanio F., Bellastella A., Serio M. Elevated serum interferon-gamma-inducible chemokine-10/CXC chemokine ligand-10 in autoimmune primary adrenal insufficiency and in vitro expression in human adrenal cells primary cultures after stimulation with proinflammatory cytokines. J. Clin. Endocrinol. Metab. 2005, 90(4):2357-2363.
53. Rottembourg D., Deal C., Lambert M., Mallone R., Carel J.C., Lacroix A., Caillat-Zucman S., le Deist F. 21-Hydroxylase epitopes are targeted by CD8 T cells in autoimmune Addison's disease. J. Autoimmun. 2010, 35(4):309-315.
54. Sankar S., Chan H., Romanow W.J., Li J., Bates R.J. IKK-i signals through IRF3 and NFkappaB to mediate the production of inflammatory cytokines. Cell. Signal. 2006, 18(7):982-993.
55. Simonian M.H., White M.L., Gill G.N. Growth and function of cultured bovine adrenocortical cells in a serum-free defined medium. Endocrinology 1982, 111(3):919-927.
56. Skinningsrud B., Husebye E.S., Gervin K., Lovas K., Blomhoff A., Wolff A.B., Kemp E.H., Egeland T., Undlien D.E. Mutation screening of PTPN22: association of the 1858T-allele with Addison's disease. Eur. J. Hum. Genet. 2008, 16(8):977-982.
57. Skinningsrud B., Lie B.A., Lavant E., Carlson J.A., Erlich H., Akselsen H.E., Gervin K., Wolff A.B., Erichsen M.M., Lovas K., Husebye E.S., Undlien D.E. Multiple loci in the HLA complex are associated with Addison's disease. J. Clin. Endocrinol. Metab. 2011.
58. Slinker B.K. The statistics of synergism. J. Mol. Cell. Cardiol. 1998, 30(4):723-731.
59. Thomas E., Gonzalez V.D., Li Q., Modi A.A., Chen W., Noureddin M., Rotman Y., Liang T.J. HCV infection induces a unique hepatic innate immune response associated with robust production of type III interferons. Gastroenterology 2012, 142(4):978-988.
60. Tran N., Koch A., Berkels R., Boehm O., Zacharowski P.A., Baumgarten G., Knuefermann P., Schott M., Kanczkowski W., Bornstein S.R., Lightman S.L., Zacharowski K. Toll-like receptor 9 expression in murine and human adrenal glands and possible implications during inflammation. J. Clin. Endocrinol. Metab. 2007, 92(7):2773-2783.
61. Trevisan M., Matkovic U., Cusinato R., Toppo S., Palu G., Barzon L. Human cytomegalovirus productively infects adrenocortical cells and induces an early cortisol response. J. Cell. Physiol. 2009, 221(3):629-641.
62. Winqvist O., Karlsson F.A., Kampe O. 21-Hydroxylase, a major autoantigen in idiopathic Addison's disease. Lancet 1992, 339(8809):1559-1562.